Oryzon Genomics
Biotechnology Research • 
Cornellà de Llobregat, Catalonia, Spain • 51-100 Employees
Company overview
| Headquarters | Calle de Sant Ferran, 74, Cornellà de Llobregat, Catalonia 08940, ES |
| Phone number | +34935151313 |
| Website | |
| SIC | 283 |
| Keywords | Clinical Trials, Cancer, Drug Discovery And Development, Neurodegeneration, Biomarker Discovery, Epigenetics |
| Founded | 2000 |
| Employees | 51-100 |
| Socials |
Key Contacts at Oryzon Genomics
Jordi Salas
Cmc Director
Margarida Mas
Subdirector Financiero Deputy Financial Manager - Dfm
Sonia Gutiérrez Bezón
Director Of Clinical Operations
Emili Torrell
Director Business Development & Licensing Bdo
Emili Torrell
Director Business Development
Oryzon Genomics Email Formats
Oryzon Genomics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@oryzon.com), used 54.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@oryzon.com | 54.3% |
{first name}{last name} | johndoe@oryzon.com | 28.6% |
{first initial}{second initial} | jo@oryzon.com | 11.4% |
{last name}{last name} | doedoe@oryzon.com | 5.7% |
About Oryzon Genomics
Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.
Oryzon Genomics revenue & valuation
| Annual revenue | $4,962,190 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $15,900,000 |
| Total funding | $50,198,700 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Oryzon Genomics has 26 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Oryzon Genomics's funding history, including investment rounds, total capital raised, and key backers.
Oryzon Genomics Tech Stack
Discover the technologies and tools that power Oryzon Genomics's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript libraries
Tag managers
Webmail
JavaScript libraries
Programming languages
Security
CMS
Security
UI frameworks
Analytics
Miscellaneous
United States
Martinique
AustraliaFrequently asked questions
4.8
40,000 users
